“…One could envisage administering unmodified short-term progenitors which, having been spared ex vivo culture and transduction, should ensure faster reconstitution, admixed with transduced HSC, which would progressively replace the graft with gene-modified progeny (Zonari et al, 2017). Whereas HSC GT has been performed until now with cells purified according to surface expression of the CD34 marker, we can envisage exploring new protocols that further enrich for the repopulating HSPC fraction by adding other markers to the selection profile, provided that clinically compliant technologies for multi-parametric cell sorting coupled with advanced microfluidics become available (Notta et al, 2011;Fares et al, 2017;Radtke et al, 2017). Whereas HSC GT has been performed until now with cells purified according to surface expression of the CD34 marker, we can envisage exploring new protocols that further enrich for the repopulating HSPC fraction by adding other markers to the selection profile, provided that clinically compliant technologies for multi-parametric cell sorting coupled with advanced microfluidics become available (Notta et al, 2011;Fares et al, 2017;Radtke et al, 2017).…”